CN111956792A - 一种一指肽肽抑菌片制备方法 - Google Patents
一种一指肽肽抑菌片制备方法 Download PDFInfo
- Publication number
- CN111956792A CN111956792A CN202010906810.9A CN202010906810A CN111956792A CN 111956792 A CN111956792 A CN 111956792A CN 202010906810 A CN202010906810 A CN 202010906810A CN 111956792 A CN111956792 A CN 111956792A
- Authority
- CN
- China
- Prior art keywords
- percent
- alum
- peptide
- mixing
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 30
- 230000003385 bacteriostatic effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000008434 yi-zhi Substances 0.000 title claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229940037003 alum Drugs 0.000 claims abstract description 40
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 30
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 21
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 15
- 108010035532 Collagen Proteins 0.000 claims abstract description 15
- OLGWXCQXRSSQPO-MHARETSRSA-N P(1),P(4)-bis(5'-guanosyl) tetraphosphate Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=C(NC2=O)N)=C2N=C1 OLGWXCQXRSSQPO-MHARETSRSA-N 0.000 claims abstract description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 15
- 229920002472 Starch Polymers 0.000 claims abstract description 15
- 229920001436 collagen Polymers 0.000 claims abstract description 15
- OLGWXCQXRSSQPO-UHFFFAOYSA-N diguanosine tetraphosphate Natural products C1=NC(C(N=C(N)N2)=O)=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OCC(C(O)C1O)OC1N1C=NC2=C1NC(N)=NC2=O OLGWXCQXRSSQPO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 15
- 239000008107 starch Substances 0.000 claims abstract description 15
- 235000019698 starch Nutrition 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 12
- 241001313857 Bletilla striata Species 0.000 claims abstract description 10
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 10
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 8
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 40
- 239000008187 granular material Substances 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 23
- 239000011812 mixed powder Substances 0.000 claims description 20
- 230000000844 anti-bacterial effect Effects 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 10
- 239000011265 semifinished product Substances 0.000 claims description 10
- 229940032147 starch Drugs 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229940080313 sodium starch Drugs 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 241000222122 Candida albicans Species 0.000 abstract description 4
- 241000588724 Escherichia coli Species 0.000 abstract description 4
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 4
- 229940095731 candida albicans Drugs 0.000 abstract description 4
- 210000001215 vagina Anatomy 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000009545 invasion Effects 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 201000008100 Vaginitis Diseases 0.000 description 9
- 206010046914 Vaginal infection Diseases 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种一指肽肽抑菌片制备方法,包括如下制备步骤:步骤1:白芨提取物3%‑3.5%、白芍提取物4.5%‑5%、生物肽1%‑1.5%、胶原蛋白12.5%‑13%、透明质酸钠10%‑10.5%、四磷酸二鸟苷0.3%‑0.05%、醋酸氯已定0.3%‑0.5%、碳酸氢钠20%‑21%、白矾19%‑19.5%、柠檬酸4%‑5%、淀粉22%‑22.4%、硬脂酸镁1%‑1.4%。本发明制备过程高效无毒,而且在使用过程中不会对人体及物品产生不良影响,对大肠杆菌、白色念珠菌和金黄色葡萄球菌的抑菌率均可以达到50%以上,明显提高杀菌抑菌效果,使其有效的抑制病菌生长,减少病菌侵害,保护女性阴道。
Description
技术领域
本发明涉及医药相关技术领域,具体为一种一指肽肽抑菌片制备方法。
背景技术
妇科外阴、阴道炎症是一种常见病、多发病。调查显示,全世界约87%的成年女性不同程度的感染过妇科炎症,临床常见的妇科炎症有阴道炎、宫颈炎、子宫内膜炎等。临床上妇科炎症主要表现为阴部瘙痒、灼热肿痛、白带增多、尿频、尿急、尿痛、气味异常等症状,反复发作,经久不愈,影响到日常工作及与人的交往,给患者带来严重的生理和心理负担;常见的阴道炎有细菌性阴道炎、滴虫性阴道炎、霉菌性阴道炎、老年性阴道炎,相关医学组织曾对1181例阴道炎进行研究,发现41%为细菌性,27%为真菌性,24%为滴虫性,因此采用抑菌片对于阴道炎的治疗具有良好的嘴用。
但是,现有的一些抑菌片大多主要采用醋酸氯己定、碳酸氢钠和柠檬酸作为主要原料,配方单一,无法对女性阴道进行有效的抑菌和杀菌作用,从而不能有效抑菌病菌的生产,治疗效果不佳,需要进行改进。
发明内容
本发明的目的在于提供一种一指肽肽抑菌片制备方法,以解决上述背景技术中提出的问题。
为了解决上述技术问题,本发明提供如下技术方案:一种一指肽肽抑菌片制备方法,包括如下制备步骤:
步骤1:白芨提取物3%-3.5%、白芍提取物4.5%-5%、生物肽1%-1.5%、胶原蛋白12.5%-13%、透明质酸钠10%-10.5%、四磷酸二鸟苷0.3%-0.05%、醋酸氯已定0.3%-0.5%、碳酸氢钠20%-21%、白矾19%-19.5%、柠檬酸4%-5%、淀粉22%-22.4%、硬脂酸镁1%-1.4%;
步骤2:去适量的白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠加入到混合机构内进行混合,制成1号混合粉备用;
步骤3:将白矾放入粉碎机构内进行粉碎,得到白矾粉颗粒,然后在白矾颗粒中加入四磷酸二鸟苷进行混合,制成2号混合粉备用;
步骤4:将1号混合粉、2号混合粉与碳酸氢钠和淀粉进行充分搅拌混合,并将充分混合后的原料进行制粒、整粒;
步骤5:将步骤4制得的颗粒过14目筛,然后将过筛的颗粒进行干燥,得到半成品颗粒;
步骤6:在半成品颗粒中,加入硬脂酸镁、醋酸氯已定和柠檬酸,将半成品颗粒与硬脂酸镁、醋酸氯已定、柠檬酸混合均匀,然后进行压片,得到抑菌片成品;
步骤7:将抑菌片依次经过装袋、装盒、装箱,完成包装。
进一步的,由下列重量份原料组成,白芨提取物3%、白芍提取物5%、生物肽1%、胶原蛋白13%、透明质酸钠10%、四磷酸二鸟苷0.05%、醋酸氯已定0.05%、碳酸氢钠20%、白矾19.5%、柠檬酸5%、淀粉22.4%、硬脂酸镁1%。
进一步的,步骤3中,将白矾粉碎后需要过40目筛,去除粉碎后的大颗粒白矾,使得白矾颗粒均匀。
进一步的,步骤4中,混合时混合时间为15-20分钟,混合电机的转速为680r/min-760r/min。
进一步的,步骤5中,干燥时的干燥温度为65℃-75℃,干燥时间为20-30分钟。
进一步的,步骤6中,压片工作时,单片抑菌片的的重量为0.25g。
与现有技术相比,本发明所达到的有益效果是:本发明所提供的一指肽肽抑菌片制备方法,制备过程高效无毒,而且在使用过程中不会对人体及物品产生不良影响,通过添加白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠、四磷酸二鸟苷、醋酸氯已定、碳酸氢钠、白矾、柠檬酸、淀粉和硬脂酸镁,对大肠杆菌、白色念珠菌和金黄色葡萄球菌的抑菌率均可以达到50%以上,明显提高杀菌抑菌效果,使其有效的抑制病菌生长,减少病菌侵害,保护女性阴道,达到抑菌抗菌的目的,且该种泡腾抑菌片重量在0.25克,重量极小,使用过程中可有效的减少患者的不适感。
附图说明
附图用来提供对本发明的进一步理解,并且构成说明书的一部分,与本发明的实施例一起用于解释本发明,并不构成对本发明的限制。在附图中:
图1是本发明的制备工艺流程结构示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
一种一指肽肽抑菌片制备方法,包括如下制备步骤:
步骤1:白芨提取物3%、白芍提取物5%、生物肽1%、胶原蛋白13%、透明质酸钠10%、四磷酸二鸟苷0.05%、醋酸氯已定0.05%、碳酸氢钠20%、白矾19.5%、柠檬酸5%、淀粉22.4%、硬脂酸镁1%;
步骤2:去适量的白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠加入到混合机构内进行混合,制成1号混合粉备用;
步骤3:将白矾放入粉碎机构内进行粉碎,得到白矾粉颗粒,并将粉碎后的白矾颗粒过40目筛,去除粉碎后的大颗粒白矾,使得白矾颗粒均匀,然后在白矾颗粒中加入四磷酸二鸟苷进行混合,制成2号混合粉备用;
步骤4:将1号混合粉、2号混合粉与碳酸氢钠和淀粉进行充分搅拌混合,并将充分混合后的原料进行制粒、整粒,混合时,混合时间为15分钟,混合电机的转速为760r/min;
步骤5:将步骤4制得的颗粒过14目筛,然后将过筛的颗粒进行干燥,得到半成品颗粒,其中,干燥时的干燥温度为65℃,干燥时间为30分钟;
步骤6:在半成品颗粒中,加入硬脂酸镁、醋酸氯已定和柠檬酸,将半成品颗粒与硬脂酸镁、醋酸氯已定、柠檬酸混合均匀,然后进行压片,得到抑菌片成品;压片工作时,单片抑菌片的的重量为0.25g;
步骤7:将抑菌片依次经过装袋、装盒、装箱,完成包装。
实施例2:
一种一指肽肽抑菌片制备方法,包括如下制备步骤:
步骤1:白芨提取物3.2%、白芍提取物4.8%、生物肽1.3%、胶原蛋白12.8%、透明质酸钠10.3%、四磷酸二鸟苷0.03%、醋酸氯已定0.05%、碳酸氢钠20.4%、白矾19.32%、柠檬酸4.6%、淀粉22%、硬脂酸镁1.2%;
步骤2:去适量的白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠加入到混合机构内进行混合,制成1号混合粉备用;
步骤3:将白矾放入粉碎机构内进行粉碎,得到白矾粉颗粒,并将粉碎后的白矾颗粒过40目筛,去除粉碎后的大颗粒白矾,使得白矾颗粒均匀,然后在白矾颗粒中加入四磷酸二鸟苷进行混合,制成2号混合粉备用;
步骤4:将1号混合粉、2号混合粉与碳酸氢钠和淀粉进行充分搅拌混合,并将充分混合后的原料进行制粒、整粒;其中,混合时混合时间为17分钟,混合电机的转速为720r/min
步骤5:将步骤4制得的颗粒过14目筛,然后将过筛的颗粒进行干燥,得到半成品颗粒;其中,干燥时的干燥温度为70℃,干燥时间为25分钟
步骤6:在半成品颗粒中,加入硬脂酸镁、醋酸氯已定和柠檬酸,将半成品颗粒与硬脂酸镁、醋酸氯已定、柠檬酸混合均匀,然后进行压片,得到抑菌片成品;压片工作时,单片抑菌片的的重量为0.25g。
步骤7:将抑菌片依次经过装袋、装盒、装箱,完成包装。
实施例3:
一种一指肽肽抑菌片制备方法,包括如下制备步骤:
步骤1:白芨提取物3.5%、白芍提取物4.6%、生物肽1.5%、胶原蛋白12.6、透明质酸钠10.51%、四磷酸二鸟苷0.05%、醋酸氯已定0.04%、碳酸氢钠20.6%、白矾19%、柠檬酸4%、淀粉22.2%、硬脂酸镁1.4%;
步骤2:去适量的白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠加入到混合机构内进行混合,制成1号混合粉备用;
步骤3:将白矾放入粉碎机构内进行粉碎,得到白矾粉颗粒,并将粉碎后的白矾颗粒过40目筛,去除粉碎后的大颗粒白矾,使得白矾颗粒均匀,然后在白矾颗粒中加入四磷酸二鸟苷进行混合,制成2号混合粉备用;
步骤4:将1号混合粉、2号混合粉与碳酸氢钠和淀粉进行充分搅拌混合,并将充分混合后的原料进行制粒、整粒;其中,混合时混合时间为20分钟,混合电机的转速为680r/min。
步骤5:将步骤4制得的颗粒过14目筛,然后将过筛的颗粒进行干燥,得到半成品颗粒;干燥时的干燥温度为75℃,干燥时间为20分钟;
步骤6:在半成品颗粒中,加入硬脂酸镁、醋酸氯已定和柠檬酸,将半成品颗粒与硬脂酸镁、醋酸氯已定、柠檬酸混合均匀,然后进行压片,得到抑菌片成品;压片工作时,单片抑菌片的的重量为0.25g;
步骤7:将抑菌片依次经过装袋、装盒、装箱,完成包装。
将实施例1-3制备的成品进行检测得到数据如下表所示:
综上所述:本发明所提供的一指肽肽抑菌片制备方法,制备过程高效无毒,而且在使用过程中不会对人体及物品产生不良影响,通过添加白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠、四磷酸二鸟苷、醋酸氯已定、碳酸氢钠、白矾、柠檬酸、淀粉和硬脂酸镁,对大肠杆菌、白色念珠菌和金黄色葡萄球菌的抑菌率均可以达到50%以上,明显提高杀菌抑菌效果,使其有效的抑制病菌生长,减少病菌侵害,保护女性阴道,达到抑菌抗菌的目的。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种一指肽肽抑菌片制备方法,其特征在于,包括如下制备步骤:
步骤1:白芨提取物3%-3.5%、白芍提取物4.5%-5%、生物肽1%-1.5%、胶原蛋白12.5%-13%、透明质酸钠10%-10.5%、四磷酸二鸟苷0.03%-0.05%、醋酸氯已定0.03%-0.05%、碳酸氢钠20%-21%、白矾19%-19.5%、柠檬酸4%-5%、淀粉22%-22.4%、硬脂酸镁1%-1.4%;
步骤2:去适量的白芨提取物、白芍提取物、生物肽、胶原蛋白、透明质酸钠加入到混合机构内进行混合,制成1号混合粉备用;
步骤3:将白矾放入粉碎机构内进行粉碎,得到白矾粉颗粒,然后在白矾颗粒中加入四磷酸二鸟苷进行混合,制成2号混合粉备用;
步骤4:将1号混合粉、2号混合粉与碳酸氢钠和淀粉进行充分搅拌混合,并将充分混合后的原料进行制粒、整粒;
步骤5:将步骤4制得的颗粒过14目筛,然后将过筛的颗粒进行干燥,得到半成品颗粒;
步骤6:在半成品颗粒中,加入硬脂酸镁、醋酸氯已定和柠檬酸,将半成品颗粒与硬脂酸镁、醋酸氯已定、柠檬酸混合均匀,然后进行压片,得到抑菌片成品;
步骤7:将抑菌片依次经过装袋、装盒、装箱,完成包装。
2.根据权利要求1所述的一种一指肽肽抑菌片制备方法,其特征在于:由下列重量份原料组成,白芨提取物3%、白芍提取物5%、生物肽1%、胶原蛋白13%、透明质酸钠10%、四磷酸二鸟苷0.05%、醋酸氯已定0.05%、碳酸氢钠20%、白矾19.5%、柠檬酸5%、淀粉22.4%、硬脂酸镁1%。
3.根据权利要求1所述的一种一指肽肽抑菌片制备方法,其特征在于:步骤3中,将白矾粉碎后需要过40目筛,去除粉碎后的大颗粒白矾,使得白矾颗粒均匀。
4.根据权利要求1所述的一种一指肽肽抑菌片制备方法,其特征在于:步骤4中,混合时混合时间为15-20分钟,混合电机的转速为680r/min-760r/min。
5.根据权利要求1所述的一种一指肽肽抑菌片制备方法,其特征在于:步骤5中,干燥时的干燥温度为65℃-75℃,干燥时间为20-30分钟。
6.根据权利要求1所述的一种一指肽肽抑菌片制备方法,其特征在于:步骤6中,压片工作时,单片抑菌片的的重量为0.25g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010906810.9A CN111956792A (zh) | 2020-09-01 | 2020-09-01 | 一种一指肽肽抑菌片制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010906810.9A CN111956792A (zh) | 2020-09-01 | 2020-09-01 | 一种一指肽肽抑菌片制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111956792A true CN111956792A (zh) | 2020-11-20 |
Family
ID=73391629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010906810.9A Pending CN111956792A (zh) | 2020-09-01 | 2020-09-01 | 一种一指肽肽抑菌片制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111956792A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103031716A (zh) * | 2011-09-30 | 2013-04-10 | 天津市中科健新材料技术有限公司 | 一种用于净味湿巾的整理液 |
WO2014058084A1 (ko) * | 2012-10-09 | 2014-04-17 | 주식회사 바이오리더스 | 감마올리고펩타이드 또는 그 염을 함유하는 주름개선용 화장료 조성물 |
CN103751532A (zh) * | 2013-10-17 | 2014-04-30 | 杜江 | 一种治疗妇科炎症的中药组合物及其制备方法 |
CN104703581A (zh) * | 2012-09-14 | 2015-06-10 | 克洛克斯科技公司 | 美容生物光子组合物 |
CN104721116A (zh) * | 2015-02-12 | 2015-06-24 | 宝健(北京)生物技术有限公司 | 一种具有抗衰老功效的组合物及其制备方法和应用 |
CN105456113A (zh) * | 2015-12-16 | 2016-04-06 | 贵州理工学院 | 美白水凝胶保健面膜及其制备工艺 |
CN105560389A (zh) * | 2015-12-30 | 2016-05-11 | 广州暨南生物医药研究开发基地有限公司 | 一种具有止痒效果的妇科清洗液及其制备方法 |
CN106466235A (zh) * | 2015-08-11 | 2017-03-01 | 珠海市恒自然本草技术研究院 | 一种洗颜粉 |
CN108014287A (zh) * | 2018-02-02 | 2018-05-11 | 上海哈美实业发展有限公司 | 一种泡腾抑菌片及其制备方法 |
-
2020
- 2020-09-01 CN CN202010906810.9A patent/CN111956792A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103031716A (zh) * | 2011-09-30 | 2013-04-10 | 天津市中科健新材料技术有限公司 | 一种用于净味湿巾的整理液 |
CN104703581A (zh) * | 2012-09-14 | 2015-06-10 | 克洛克斯科技公司 | 美容生物光子组合物 |
WO2014058084A1 (ko) * | 2012-10-09 | 2014-04-17 | 주식회사 바이오리더스 | 감마올리고펩타이드 또는 그 염을 함유하는 주름개선용 화장료 조성물 |
CN103751532A (zh) * | 2013-10-17 | 2014-04-30 | 杜江 | 一种治疗妇科炎症的中药组合物及其制备方法 |
CN104721116A (zh) * | 2015-02-12 | 2015-06-24 | 宝健(北京)生物技术有限公司 | 一种具有抗衰老功效的组合物及其制备方法和应用 |
CN106466235A (zh) * | 2015-08-11 | 2017-03-01 | 珠海市恒自然本草技术研究院 | 一种洗颜粉 |
CN105456113A (zh) * | 2015-12-16 | 2016-04-06 | 贵州理工学院 | 美白水凝胶保健面膜及其制备工艺 |
CN105560389A (zh) * | 2015-12-30 | 2016-05-11 | 广州暨南生物医药研究开发基地有限公司 | 一种具有止痒效果的妇科清洗液及其制备方法 |
CN108014287A (zh) * | 2018-02-02 | 2018-05-11 | 上海哈美实业发展有限公司 | 一种泡腾抑菌片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
张春霞等: "阴道炎治疗药物及其外用制剂研究进展", 世界临床药物, vol. 31, no. 6, pages 381 - 386 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104688648B (zh) | 一种口腔用组合物及其制备方法 | |
CN110075036A (zh) | 抗口腔幽门螺杆菌药物牙膏 | |
KR101951733B1 (ko) | 프로폴리스 및 천연 추출물을 포함하는 여성 청결제용 조성물 및 이의 제조 방법 | |
CN106309401A (zh) | 一种用于预防和治疗皮肤疾病的沐浴泡腾片 | |
CN107982277B (zh) | 一种复合抗菌气雾剂及其制备方法和应用 | |
CN112316017A (zh) | 一种妇科抑菌凝胶及其制备方法 | |
CN113576961A (zh) | 一种沉香牙膏及其制备方法 | |
CN107496977B (zh) | 一种用纯天然植物提取物制备的液体敷料及其制备方法 | |
WO2015062156A1 (zh) | 一种食药用真菌纳米膜的制备方法及其应用 | |
CN111991612A (zh) | 一种具有镇痛、抗菌功能的液体敷料制备方法 | |
CN107929393A (zh) | 壳寡糖润喉口腔压片及其制备方法 | |
CN109223760B (zh) | 一种苯并呋喃衍生物的用途 | |
CN111956792A (zh) | 一种一指肽肽抑菌片制备方法 | |
CN114306526B (zh) | 一种复方苦丁茶中药提取物及其在制备沐浴露或洗手液中的应用 | |
CN102716060B (zh) | 松针粉-超细微晶纤维素爽身粉及其制造方法 | |
CN106692755B (zh) | 一种具有止血消炎抗菌的中药组合物及其制备方法和应用 | |
KR102346809B1 (ko) | 소금 및 아시아홀리오크충영 추출물을 포함하는 여성 청결제 | |
CN108785374A (zh) | 清香桂皮肤抑菌凝胶及其制备方法 | |
CN109010353A (zh) | 一种治疗放化疗患者口腔粘膜溃疡的生物多糖材料组合物 | |
CN101007130B (zh) | 一种抗菌消炎的中药组合物及其制备方法 | |
JP2013133287A (ja) | 粉粒状複合体及び創傷被覆材 | |
CN102462768A (zh) | 一种女性外用护理液 | |
CN106581172B (zh) | 用于防治霉菌性、滴虫性和老年性阴道炎的药物及制备方法 | |
CN105055713A (zh) | 一种预防或治疗褥疮的药物组合物及其制备方法 | |
CN106420923B (zh) | 一种黄芩酮生物活性作用物与聚六亚甲基双胍组合消毒液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |
|
RJ01 | Rejection of invention patent application after publication |